Mike Walsh
Five PHRI studies are among the 11 successful applications (out of 43 submitted from across Canada) for funding provided by the ACT Consortium for clinical trials.
Almost four dozen outstanding applications were submitted from across the country. Targeted peer review looked for: public reporting of the trial by Jan. 2025; high-quality design and execution; and high probability that the trial will lead to meaningful impact.
Principal investigators of the funded PHRI studies are:
PHRI Scientist Mike Walsh and team are determining if spironolactone (an inexpensive, widely available mineralocorticoid receptor antagonist) reduces cardiovascular deaths and heart failure hospitalizations in patients with kidney failure in an international, placebo controlled, randomized controlled trial called the Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE).
Jessica Spence
PHRI Senior Scientist Jeff Healey for the ARTESIA trial investigating if treatment with apixaban, compared with aspirin, will reduce the risk of stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke.
PHRI Investigator Jessica Spence for B-Free to investigate benzodiazepine-free cardiac anesthesia for the reduction of postoperative delirium in the ICU.
PHRI Scientist Sanjit Jolly for his study of colchicine and spironolactone in patients with acute myocardial infarction in the CLEAR trial.
PHRI Scientist David Conen for investigating colchicine for prevention of perioperative AF in patients undergoing thoracic surgery (COP-AF).
